Schizophrenia Research
Volume 120, Issue 1 , Pages 1-6 , July 2010

The psychosis threshold in Ultra High Risk (prodromal) research: Is it valid?

  • Alison R. Yung

      Affiliations

    • Orygen Youth Health Research Centre, University of Melbourne, Parkville, Australia
    • Corresponding Author InformationCorresponding author. Orygen Youth Health Research Centre, University of Melbourne, 35 Poplar Rd, Parkville 3052, Victoria, Australia. Tel.: +61 3 93422800; fax: +61 3 93422921.
    • ,
  • Barnaby Nelson

      Affiliations

    • Orygen Youth Health Research Centre, University of Melbourne, Parkville, Australia
    • ,
  • Andrew Thompson

      Affiliations

    • Orygen Youth Health Research Centre, University of Melbourne, Parkville, Australia
    • ,
  • Stephen J. Wood

      Affiliations

    • Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, Australia

Received 28 October 2009 ,Revised 8 January 2010 ,Accepted 12 March 2010.

References 

  1. Amminger GP, Schaefer MR, Papageorgiou K, Becker J, Mossaheb N, Harrigan SM, et al. Omega-3 fatty acids reduce the risk of early transition to psychosis in ultra-high risk individuals: a double-blind randomized, placebo-controlled treatment study. Schizophrenia Bulletin. 2007;33:418–419
  2. Bechdolf A, Veith V, Schwarzer D, Schormann M, Stamm E, Janssen B, et al. Cognitive-behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Research. 2005;136:251–255
  3. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. The American Journal of Psychiatry. 1993;150:1349–1354
  4. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry. 2005;20:372–378
  5. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry. 2008;65:28–37
  6. Carpenter WT. Anticipating DSM-V: should psychosis risk become a diagnostic class?. Schizophrenia Bulletin. 2009;35:841–843
  7. Claridge G. The schizophrenias as nervous types. The British Journal of Psychiatry. 1972;121:1–17
  8. Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophrenia Research. 2002;54:177–186
  9. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophrenia Bulletin. 2003;29:633–651
  10. Hafner H, Maurer K, Trendler G, Heiden WAD, Schmidt M, Konnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases—a controlled study of schizophrenia, depression and healthy controls. Schizophrenia Research. 2005;77:11–24
  11. Hawkins KA, Keefe RS, Christensen BK, et al. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research. 2008;105:1–9
  12. Heckers S. Who is at risk for a psychotic disorder?. Schizophrenia Bulletin. 2009;35:847–850
  13. Job DE, Whalley H, Johnstone EC, Lawrie SM. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage. 2005;25:1023–1030
  14. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry. 2001;50:884–897
  15. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry. 2006;163:790–799
  16. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry. 2002;59:921–928
  17. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry. 2002;159:863–865
  18. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin. 2003;29:703–715
  19. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry. 2004;185:291–297
  20. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultra high risk. Schizophrenia Bulletin. 2007;33:682–687
  21. Nelson B, Yung AR. Psychotic-like experiences as overdetermined phenomena: when do they increase risk for psychotic disorder. Schizophrenia Research. 2009;108:303–304
  22. Niendam TA, Jalbzrikowski M, Bearden CE. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychological Review. 2009;19:280–293
  23. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatrica Scandinavica. 2006;113:247–272
  24. Pantelis C, Velakoulis D, McGorry P, Wood SJ, Suckling J, Phillips LJ, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet. 2003;361:281–288
  25. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at Ultra High Risk of psychosis. Schizophrenia Research. 2007;96:25–33
  26. Ruhrmann S. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry. 2007;191:S88–S95
  27. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36:S162–S167
  28. Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, et al. Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophrenia Research. 2009;108:85–92
  29. Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, et al. Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. The Archives of General Psychiatry. 2009;66:366–376
  30. van Os J, Hanssen M, de Graaf R, Vollebergh W. Does the urban environment independently increase the risk for both negative and positive features of psychosis?. Social Psychiatry and Psychiatric Epidemiology. 2002;37:460–464
  31. Walterfang M, McGuire PK, Yung A, Phillips L, Velakoulis D, Wood SJ, et al. White matter volume changes in people who develop psychosis. British Journal of Psychiatry. 2008;193:210–215
  32. Wood SJ, Brewer W, Koutsouradis P, Phillips LJ, Francey SM, Proffitt T, et al. Cognitive decline following psychosis onset: data from the PACE clinic. British Journal of Psychiatry. 2007;191(suppl 51):52–57
  33. Woods S, Addington J, Cadenhead K, Cannon T, Cornblatt B, Heinssen B, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin. 2009;894–908
  34. www.schizophreniaforum.org, 2009. Is the risk syndrome for psychosis risky business? Accessed 26 July 2009.
  35. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin. 1996;22:353–370
  36. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin. 1996;22:283–303
  37. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophrenia Research. 2003;60:21–32
  38. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research. 2004;67:131–142
  39. Yung AR, Yuen HP, McGorry PD, Phillips L, Kelly D, Dell'Olio M, et al. Mapping the onset of psychosis — the Comprehensive Assessment of At Risk Mental States (CAARMS). The Australian and New Zealand Journal of Psychiatry. 2005;39:964–971
  40. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the Ultra High Risk (Prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophrenia Research. 2006;84:57–66
  41. Yung AR, Buckby JA, Cosgrave EM, Killackey EJ, Baker K, Cotton SM, et al. Association between psychotic experiences and depression in a clinical sample over 6months. Schizophrenia Research. 2007;91:246–253
  42. Yung AR, Nelson B, Baker K, Buckby J, Baksheev G, Cosgrave E. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. The Australian and New Zealand Journal of Psychiatry. 2009;43:118–128

PII: S0920-9964(10)01184-9

doi: 10.1016/j.schres.2010.03.014

Schizophrenia Research
Volume 120, Issue 1 , Pages 1-6 , July 2010

Article Tools

* Image Usage & Resolution